SAVA News and Press, Cassava Sciences Inc. From 10/25/23

Safety Finding Based on Blinded MRI Brain Data at Week 40 ARIA is a Known Risk Factor for Anti-Amyloid Antibody Drugs MRI Data Presented at the 16 th CTAD Conference in Boston, MA AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: ...

ATLANTA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) complied with federal securities laws.  On October 12, 2023, Science reported that, following an inv...

Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares are currently up 10.92% on the day to $14.02. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simuf...

2023-10-14 15:00:00 ET Weight loss drugs seen impacting container, packaging companies Weight loss drugs may lead to reduced food consumption - watch these stocks Kellanova paying attention to potential threats from weight loss meds Walmart says Oze...

2023-10-13 16:01:27 ET More on Cassava Sciences Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct Claims Cassava Sciences: Update Following Leaked CUNY Report, Fundamentals Remain Unchanged Cassava Sciences: Unconvincing Open Label Studies, Upcomin...

2023-10-13 13:05:06 ET A national policy that limited the use of a type of brain scan called positron emission tomography (PET) in testing for symptoms of Alzheimer's disease has been removed, the U.S. Centers for Medicare & Medicaid Services (CMS) said on Friday. The cause of the m...

2023-10-13 12:45:50 ET Shares of Cassava Sciences (NASDAQ: SAVA) were tanking Friday, down by almost 30% early in the session and still off by 11.6% as of 12:35 p.m. ET. The steep decline came after the company issued a public statement regarding an internal report prepared by the C...

2023-10-13 10:19:48 ET Summary Cassava Sciences faces regulatory and reputational challenges, specifically regarding allegations of scientific misconduct related to its Alzheimer's drug, simufilam. Despite a strong balance sheet, heightened R&D expenses and a complex regulator...

2023-10-13 09:00:58 ET Summary A leaked report by The City University of New York was published yesterday alleging research misconduct by neuroscientist Dr. Hoau-Yan Wang involved in several simufilam-related preclinical publications. Loss of raw research material (a red flag) has...

2023-10-13 08:27:23 ET More on Momentus, Phio Pharmaceuticals, etc. Momentus Inc. (MNTS) Q2 2023 Earnings Call Transcript Wheeler REIT: Gearing Up For Sharemageddon Momentus to provide orbital delivery services for RIDE! Space Momentus prices $5M stock offeri...